Pozen Migraine Combo “Not Approvable”; Imitrex Combo Could Be Affected
Executive Summary
FDA's "not approvable" letter for Pozen's naproxen/ metoclopramide migraine combination MT-100 may prompt the company to revisit the Phase III trial design for an Imitrex combo under development with GlaxoSmithKline